Home / Business and Economy / Gilead's Liver & Cancer Drugs Show Promising Trial Results
Gilead's Liver & Cancer Drugs Show Promising Trial Results
3 Jun
Summary
- Livdelzi shows durable reductions in liver markers for PBC patients.
- Hepcludex seeks accelerated US approval for chronic hepatitis delta.
- Trodelvy has positive EU opinion for metastatic triple-negative breast cancer.
In late May 2026, Gilead Sciences announced significant progress in its liver disease and oncology portfolios. New Phase 3 post hoc data revealed that Livdelzi achieved high, durable reductions in key liver markers for individuals with primary biliary cholangitis.
Concurrently, Gilead is advancing Hepcludex toward accelerated U.S. approval for treating chronic hepatitis delta. The company also secured a positive opinion from the European Union to expand the use of Trodelvy in metastatic triple-negative breast cancer.
These developments highlight Gilead's strategic consolidation in critical therapeutic areas. The company is deepening its evidence base for Livdelzi and exploring broader applications for Trodelvy, potentially in earlier treatment lines.
The company's financial outlook projects $34.5 billion in revenue and $10.8 billion in earnings by 2029. This forecast necessitates an annual revenue growth of 5.1% and an earnings increase of approximately $1.6 billion from current levels.
